Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre.

Firas Constantin KreeshanAli Al-JanabiRichard Bruce WarrenHamish John Alexander Hunter

Published in: Dermatology and therapy (2020)

Dupilumab provides an effective and safe treatment option for patients with AD. Clinical response continued to improve past 16 weeks in this real-world population. No laboratory abnormalities were felt to be secondary to dupilumab; screening and monitoring tests did not influence dupilumab prescribing.

Keyphrases

atopic dermatitis
primary care
early onset
high intensity
combination therapy